Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine

  1. Paul Naaber
  2. Liina Tserel
  3. Kadri Kangro
  4. Marite Punapart
  5. Epp Sepp
  6. Virge Jürjenson
  7. Jaanika Kärner
  8. Liis Haljasmägi
  9. Uku Haljasorg
  10. Marilin Kuusk
  11. Eve Sankovski
  12. Anu Planken
  13. Mart Ustav
  14. Eva Žusinaite
  15. Joachim M. Gerhold
  16. Kai Kisand
  17. Pärt Peterson

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.xcrm.2022.100716
  2. ScreenIT

    SciScore for 10.1101/2022.03.04.22271890: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The study has been approved by the Research Ethics Committee of the University of Tartu on February 15, 2021 (No 335/T-21).
    Consent: Participants signed informed consent before the recruitment into the study.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Antibody testing: Serum samples were analyzed for the IgG antibodies to SARS-CoV-2 Spike protein receptor-binding domain (S-RBD) IgG using quantitative Abbott SARS-CoV-2 IgG chemiluminescent micro-particle immunoassay (CLIA) on ARCHITECT i2000SR analyzer (Abbott Laboratories) as described previously 20.
    IgG
    suggested: None
    SARS-CoV-2 Spike protein receptor-binding domain (S-RBD
    suggested: None
    Software and Algorithms
    SentencesResources
    Antibody testing: Serum samples were analyzed for the IgG antibodies to SARS-CoV-2 Spike protein receptor-binding domain (S-RBD) IgG using quantitative Abbott SARS-CoV-2 IgG chemiluminescent micro-particle immunoassay (CLIA) on ARCHITECT i2000SR analyzer (Abbott Laboratories) as described previously 20.
    Abbott Laboratories
    suggested: None
    The gating strategy used Statistical analyses: GraphPad version 9 was used for statistical analyses and generation of box and whiskers plots and correlation plots.
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.03.04.22271890 on medRxiv